Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Immunogenic West Nile Virus-Like Particles

Posted May 10 2009 5:00pm

Description of Invention:
Currently, no specific vaccine or therapy for West Nile Virus (WNV) is available for human use; a killed-virus vaccine and booster is in use for horses (efficacy not yet reported). Virus-like particles (VLPs) are an exciting new strategy, as it combines the safety of killed-virus and DNA-based vaccines with the potential for immunogenicity of live-attenuated virus. VLPs have been used in approved vaccine for humans, including human papilloma virus (HPV). Generating VLPs for West Nile Virus, however, has proven difficult.

The inventors have successfully generated West Nile VLPs in insect cells by using recombinant baculoviruses expressing the WNV structural proteins prME or CprME. Mice immunized with purified West Nile VLPs developed antibodies specific to WNV with potent neutralizing activities; moreover, the mice showed no morbidity or mortality after a subsequent challenge with live WNV and showed no evidence of viremia or viral RNA in the spleen or brain.

The patent application covers applications ranging from pharmaceutical/vaccine preparations for WNV-LPs to methods for making and using them.

Applications:
Antiviral therapies, vaccines, and diagnostic kits based on West Nile VLPs.

Advantages:
  • Demonstrated efficacy in mice
  • Noninfectious
  • Manufacture using insect cells is simple and inexpensive
  • Vaccines or therapeutics are a preferable means to control infection versus the current method (reduce mosquito populations using toxic pesticides)
  • First successful generation of West Nile VLPs


Development Status:
Successful completion of proof-of-principle tests in mice.

Inventors:
Tsanyang (Jake) Liang (NIDDK)


Patent Status:
HHS, Reference No. E-352-2003/0
PCT, Application No. PCT/US2005/015319 filed 02 May 2005


Relevant Publication:
  1. M Qiao et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis. 2004 Dec 15;190(12):2104-2108. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, is seeking parties interested in collaborative research directed toward molecular strategies for vaccine and antiviral development, and animal models of viral hepatitis C. For more information, please contact Dr. T. Jake Liang at 301-496-1721, jliang@nih.gov , or Ms. Patricia Lake at 301-594-6762, lakep@mail.nih.gov .


Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Vaccines



For Additional Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 1939

Updated: 05/2009

Post a comment
Write a comment:

Related Searches